That's true, but that's not the case here. It showed no evidence for the strong benefit they were looking for (mortality), but a similar trial started in China

That's true, but that's not the case here. It showed no evidence for the strong benefit they were looking for (mortality), but a similar trial started in China before that trial, ended - and showed no change in mortality, but some shortening of the hospital stay (even though that wasn't its stated hypothesis). At that point, the western RCT remdesivir trial added the "hospital stay" target, and lo-and-behold, shortly afterwards, it turned out that it does result in no less mortality but shorter hospital stay as well. While it does give some credence to the "shorter hospital stay" result -- having reached it in to Gilead initiated RCTs -- It was statistically significant but not dramatic; And now another trial says even that's not so significant.